APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Benign Prostatic Hyperplasia (BPH) Drugs

BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.

Selected research

Market Outlook & Growth Opportunities

Global Benign Prostatic Hyperplasia (BPH) Drugs Market Outlook and Growth Opportunities 2026

Report ID 173969730430 December 2025190 pages

Choose your research edition.

Industry ResearchBenign Prostatic Hyperplasia (BPH) Drugs Industry Research Report 2026125 pages · $2,950 USDIndustry Growth & TrendsGlobal Benign Prostatic Hyperplasia (BPH) Drugs Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Benign Prostatic Hyperplasia (BPH) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Benign Prostatic Hyperplasia (BPH) Drugs Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Benign Prostatic Hyperplasia (BPH) Drugs Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

BPH is an enlarged prostate. The prostate goes through two main growth cycles during a man’s life. The first occurs early in puberty, when the prostate doubles in size. The second phase of growth starts around age 25 and goes on for most of the rest of a man's life. BPH most often occurs during this second growth phase.

North America is the largest consumption place, with a consumption market share nearly 38% in 2019. Following North America, Europe is the second largest consumption place with the consumption market share of 27.6%. Market competition is intense. Eli Lilly, GlaxoSmithKline, Astellas Pharma, Sanofi, Pfizer, etc. are the leaders of the industry, and they hold key technologies and patents, with high-end customers.

This report provides an overview of the global Benign Prostatic Hyperplasia (BPH) Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Benign Prostatic Hyperplasia (BPH) Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Benign Prostatic Hyperplasia (BPH) Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Benign Prostatic Hyperplasia (BPH) Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Benign Prostatic Hyperplasia (BPH) Drugs Segment by Company

Eli Lilly

GlaxoSmithKline

Astellas Pharma

Sanofi

Pfizer

Abbott

Allergan

TEVA

Mylan

Novartis

Merck

Benign Prostatic Hyperplasia (BPH) Drugs Segment by Type

Alpha-Blocker

Phosphodiesterase Type-5 Inhibitors

Others

Benign Prostatic Hyperplasia (BPH) Drugs Segment by Application

Hospitals

Drugstores

Others

Benign Prostatic Hyperplasia (BPH) Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Benign Prostatic Hyperplasia (BPH) Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Benign Prostatic Hyperplasia (BPH) Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Benign Prostatic Hyperplasia (BPH) Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Benign Prostatic Hyperplasia (BPH) Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Benign Prostatic Hyperplasia (BPH) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Benign Prostatic Hyperplasia (BPH) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Benign Prostatic Hyperplasia (BPH) Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Benign Prostatic Hyperplasia (BPH) Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Benign Prostatic Hyperplasia (BPH) Drugs industry.

Chapter 3: Detailed analysis of Benign Prostatic Hyperplasia (BPH) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Benign Prostatic Hyperplasia (BPH) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Benign Prostatic Hyperplasia (BPH) Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Benign Prostatic Hyperplasia (BPH) Drugs Industry Trends Table 2. Benign Prostatic Hyperplasia (BPH) Drugs Industry Drivers Table 3. Benign Prostatic Hyperplasia (BPH) Drugs Industry Opportunities and Challenges Table 4. Benign Prostatic Hyperplasia (BPH) Drugs Industry Restraints Table 5. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue Share by Company (2021-2026) Table 7. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume by Company (M Units) & (2021-2026) Table 8. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share by Company (2021-2026) Table 9. Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global Benign Prostatic Hyperplasia (BPH) Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global Benign Prostatic Hyperplasia (BPH) Drugs Key Company Manufacturing Base & Headquarters Table 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Company, Product Type & Application Table 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Benign Prostatic Hyperplasia (BPH) Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Alpha-Blocker Table 18. Significant Companies of Phosphodiesterase Type-5 Inhibitors Table 19. Significant Companies of Others Table 20. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (M Units) Table 21. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume by Type (2021-2026) & (M Units) Table 22. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume by Type (2027-2032) & (M Units) Table 23. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share by Type (2021-2026) Table 24. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share by Type (2027-2032) Table 25. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 27. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 28. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type (2021-2026) Table 29. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type (2027-2032) Table 30. Significant Companies of Hospitals Table 31. Significant Companies of Drugstores Table 32. Significant Companies of Others Table 33. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (M Units) Table 34. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume by Application (2021-2026) & (M Units) Table 35. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume by Application (2027-2032) & (M Units) Table 36. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share by Application (2021-2026) Table 37. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share by Application (2027-2032) Table 38. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application (2021-2026) Table 42. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application (2027-2032) Table 43. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region: 2021 VS 2025 VS 2032 (M Units) Table 44. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2021-2026) & (M Units) Table 45. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2021-2026) Table 46. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2027-2032) & (M Units) Table 47. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region (2027-2032) Table 48. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Region (2021-2026) Table 51. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Region (2027-2032) Table 53. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 54. Global Benign Prostatic Hyperplasia (BPH) Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 55. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country: 2021 VS 2025 VS 2032 (M Units) Table 56. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2021-2026) & (M Units) Table 58. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2021-2026) Table 59. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2027-2032) & (M Units) Table 60. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Country (2027-2032) Table 61. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Market Share by Country (2021-2026) Table 63. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Market Share by Country (2027-2032) Table 65. Eli Lilly Company Information Table 66. Eli Lilly Business Overview Table 67. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 68. Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 69. Eli Lilly Recent Development Table 70. GlaxoSmithKline Company Information Table 71. GlaxoSmithKline Business Overview Table 72. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 73. GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 74. GlaxoSmithKline Recent Development Table 75. Astellas Pharma Company Information Table 76. Astellas Pharma Business Overview Table 77. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 79. Astellas Pharma Recent Development Table 80. Sanofi Company Information Table 81. Sanofi Business Overview Table 82. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 84. Sanofi Recent Development Table 85. Pfizer Company Information Table 86. Pfizer Business Overview Table 87. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 89. Pfizer Recent Development Table 90. Abbott Company Information Table 91. Abbott Business Overview Table 92. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 94. Abbott Recent Development Table 95. Allergan Company Information Table 96. Allergan Business Overview Table 97. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 99. Allergan Recent Development Table 100. TEVA Company Information Table 101. TEVA Business Overview Table 102. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 104. TEVA Recent Development Table 105. Mylan Company Information Table 106. Mylan Business Overview Table 107. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 109. Mylan Recent Development Table 110. Novartis Company Information Table 111. Novartis Business Overview Table 112. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 114. Novartis Recent Development Table 115. Merck Company Information Table 116. Merck Business Overview Table 117. Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales (M Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio Table 119. Merck Recent Development Table 120. Key Raw Materials Table 121. Raw Materials Key Suppliers Table 122. Benign Prostatic Hyperplasia (BPH) Drugs Distributors List Table 123. Benign Prostatic Hyperplasia (BPH) Drugs Customers List Table 124. Research Programs/Design for This Report Table 125. Authors List of This Report Table 126. Secondary Sources Table 127. Primary Sources List of Figures Figure 1. Benign Prostatic Hyperplasia (BPH) Drugs Product Image Figure 2. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales (2021-2032) & (M Units) Figure 5. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global Benign Prostatic Hyperplasia (BPH) Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Alpha-Blocker Image Figure 10. Phosphodiesterase Type-5 Inhibitors Image Figure 11. Others Image Figure 12. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (M Units) Figure 13. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 14. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share by Type (2021-2032) Figure 15. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type (2021-2032) Figure 18. Hospitals Image Figure 19. Drugstores Image Figure 20. Others Image Figure 21. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (M Units) Figure 22. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share by Application (2021-2032) Figure 24. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application (2021-2032) Figure 27. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region: 2021 VS 2025 VS 2032 (M Units) Figure 28. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Value (2021-2032) & (US$ Million) Figure 32. North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Value (2021-2032) & (US$ Million) Figure 38. South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Benign Prostatic Hyperplasia (BPH) Drugs Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Benign Prostatic Hyperplasia (BPH) Drugs Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Alpha-Blocker
  • Phosphodiesterase Type-5 Inhibitors
  • Others
Applications
  • Hospitals
  • Drugstores
  • Others
Companies covered
  • Eli Lilly
  • GlaxoSmithKline
  • Astellas Pharma
  • Sanofi
  • Pfizer
  • Abbott
  • Allergan
  • TEVA
  • Mylan
  • Novartis
  • Merck

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value (2021-2032)
  4. 1.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Benign Prostatic Hyperplasia (BPH) Drugs Market Dynamics
  1. 2.1 Benign Prostatic Hyperplasia (BPH) Drugs Industry Trends
  2. 2.2 Benign Prostatic Hyperplasia (BPH) Drugs Industry Drivers
  3. 2.3 Benign Prostatic Hyperplasia (BPH) Drugs Industry Opportunities and Challenges
  4. 2.4 Benign Prostatic Hyperplasia (BPH) Drugs Industry Restraints
3 Benign Prostatic Hyperplasia (BPH) Drugs Market by Company
  1. 3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Average Price by Company (2021-2026)
  5. 3.5 Global Benign Prostatic Hyperplasia (BPH) Drugs Company Ranking (2024-2026)
  6. 3.6 Global Benign Prostatic Hyperplasia (BPH) Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global Benign Prostatic Hyperplasia (BPH) Drugs Company Product Type and Application
  8. 3.8 Global Benign Prostatic Hyperplasia (BPH) Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Benign Prostatic Hyperplasia (BPH) Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Benign Prostatic Hyperplasia (BPH) Drugs Market by Type
  1. 4.1 Benign Prostatic Hyperplasia (BPH) Drugs Type Introduction
  2. 4.1.1 Alpha-Blocker
  3. 4.1.2 Phosphodiesterase Type-5 Inhibitors
  4. 4.1.3 Others
  5. 4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume by Type
  6. 4.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  7. 4.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume by Type (2021-2032)
  8. 4.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share by Type (2021-2032)
  9. 4.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value by Type
  10. 4.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  11. 4.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value by Type (2021-2032)
  12. 4.3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type (2021-2032)
5 Benign Prostatic Hyperplasia (BPH) Drugs Market by Application
  1. 5.1 Benign Prostatic Hyperplasia (BPH) Drugs Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Drugstores
  4. 5.1.3 Others
  5. 5.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume by Application
  6. 5.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value by Application
  10. 5.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application (2021-2032)
6 Benign Prostatic Hyperplasia (BPH) Drugs Regional Sales and Value Analysis
  1. 6.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Region (2027-2032)
  5. 6.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global Benign Prostatic Hyperplasia (BPH) Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Value (2021-2032)
  12. 6.6.2 North America Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Value (2021-2032)
  21. 6.9.2 South America Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Country, 2025 VS 2032
7 Benign Prostatic Hyperplasia (BPH) Drugs Country-level Sales and Value Analysis
  1. 7.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales by Country (2027-2032)
  6. 7.4 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global Benign Prostatic Hyperplasia (BPH) Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Benign Prostatic Hyperplasia (BPH) Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Eli Lilly
  2. 8.1.1 Eli Lilly Company Information
  3. 8.1.2 Eli Lilly Business Overview
  4. 8.1.3 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Eli Lilly Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  6. 8.1.5 Eli Lilly Recent Developments
  7. 8.2 GlaxoSmithKline
  8. 8.2.1 GlaxoSmithKline Company Information
  9. 8.2.2 GlaxoSmithKline Business Overview
  10. 8.2.3 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 GlaxoSmithKline Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  12. 8.2.5 GlaxoSmithKline Recent Developments
  13. 8.3 Astellas Pharma
  14. 8.3.1 Astellas Pharma Company Information
  15. 8.3.2 Astellas Pharma Business Overview
  16. 8.3.3 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Astellas Pharma Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  18. 8.3.5 Astellas Pharma Recent Developments
  19. 8.4 Sanofi
  20. 8.4.1 Sanofi Company Information
  21. 8.4.2 Sanofi Business Overview
  22. 8.4.3 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Sanofi Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  24. 8.4.5 Sanofi Recent Developments
  25. 8.5 Pfizer
  26. 8.5.1 Pfizer Company Information
  27. 8.5.2 Pfizer Business Overview
  28. 8.5.3 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Pfizer Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  30. 8.5.5 Pfizer Recent Developments
  31. 8.6 Abbott
  32. 8.6.1 Abbott Company Information
  33. 8.6.2 Abbott Business Overview
  34. 8.6.3 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Abbott Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  36. 8.6.5 Abbott Recent Developments
  37. 8.7 Allergan
  38. 8.7.1 Allergan Company Information
  39. 8.7.2 Allergan Business Overview
  40. 8.7.3 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Allergan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  42. 8.7.5 Allergan Recent Developments
  43. 8.8 TEVA
  44. 8.8.1 TEVA Company Information
  45. 8.8.2 TEVA Business Overview
  46. 8.8.3 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 TEVA Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  48. 8.8.5 TEVA Recent Developments
  49. 8.9 Mylan
  50. 8.9.1 Mylan Company Information
  51. 8.9.2 Mylan Business Overview
  52. 8.9.3 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Mylan Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  54. 8.9.5 Mylan Recent Developments
  55. 8.10 Novartis
  56. 8.10.1 Novartis Company Information
  57. 8.10.2 Novartis Business Overview
  58. 8.10.3 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Novartis Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  60. 8.10.5 Novartis Recent Developments
  61. 8.11 Merck
  62. 8.11.1 Merck Company Information
  63. 8.11.2 Merck Business Overview
  64. 8.11.3 Merck Benign Prostatic Hyperplasia (BPH) Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Merck Benign Prostatic Hyperplasia (BPH) Drugs Product Portfolio
  66. 8.11.5 Merck Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Benign Prostatic Hyperplasia (BPH) Drugs Value Chain Analysis
  2. 9.1.1 Benign Prostatic Hyperplasia (BPH) Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Benign Prostatic Hyperplasia (BPH) Drugs Sales Mode & Process
  6. 9.2 Benign Prostatic Hyperplasia (BPH) Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Benign Prostatic Hyperplasia (BPH) Drugs Distributors
  9. 9.2.3 Benign Prostatic Hyperplasia (BPH) Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst